Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential


D'Haese J. G., Demir I. E., Friess H., Ceyhan G.

EXPERT OPINION ON THERAPEUTIC TARGETS, cilt.14, sa.2, ss.207-219, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 14 Sayı: 2
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1517/14728220903540265
  • Dergi Adı: EXPERT OPINION ON THERAPEUTIC TARGETS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.207-219
  • Anahtar Kelimeler: cancer, CX3CL1, CX3CR1, fractalkine, inflammation, neuropathic pain, therapeutic target, ATHEROSCLEROTIC LESION FORMATION, ANTITUMOR IMMUNE-RESPONSE, CORONARY-ARTERY-DISEASE, NATURAL-KILLER-CELLS, DORSAL-ROOT GANGLIA, NEUROPATHIC PAIN, CHRONIC-PANCREATITIS, SPINAL-CORD, ENDOTHELIAL-CELLS, IN-VIVO
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Importance of the field. Fractalkine, also known as CX3CL1, is the unique member of the fourth class of chemokines and mediates both chemotaxis and adhesion of inflammatory cells via its highly selective receptor CX3CR1. Fractalkine mediates inflammatory responses and pain sensation and is involved in the pathogenesis and progression of numerous inflammatory disorders and malignancies.